Compare Pfizer Inc (PFE) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs PulteGroup, Inc. — how do they compare? Pfizer Inc trades at $27.75 (market cap $159.59B), while PulteGroup, Inc. trades at $113.37 (market cap $21.40B). The key difference: Pfizer Inc is far larger — about 7.5× PulteGroup, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and PulteGroup, Inc. for 91 Days on average.
| PFE | PHM | |
|---|---|---|
Market Cap | $159.59B | $21.40B |
Volume | 30,937,010 | 2,220,826 |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $142.56 |
52-Week Low | $23.67 | $110.11 |
Typical Hold Time | 158 Days | 91 Days |
Enterprise Value | $211.09B | $21.81B |
Dividend Yield | 6.14% | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
PulteGroup (PHM) trades at $113.53, down 2.22% amid broader market weakness. The stock shows bearish technical signals with RSI at oversold levels near 19.42, while fundamentals remain solid with a P/E of 11.47 and strong profitability metrics including 14.9% ROE. Recent earnings show mixed results with Q2 2026 beating expectations but Q4 2025 and Q1 2026 missing estimates. The company maintains positive cash flow generation with $355.10M net cash flow in 2025.
PHM presents a value opportunity with attractive valuation multiples, though facing headwinds from rising mortgage rates impacting the housing sector. Analyst consensus targets $139.80 (23% upside) with 45% buy ratings, but technical indicators suggest near-term pressure. Key risks include housing market sensitivity to interest rates and margin compression from recent earnings misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
